Linda Griffith, Ph.D. is the School of Engineering Teaching Innovation Professor of Biological and Mechanical Engineering and MacVicar Fellow at MIT, where she directs the Center for Gynepathology Research and the Human Physiome on a Chip project supported by the DARPA and NIH-funded Micro-physiological Systems Program. Dr. Griffith’s research is in the field of regenerative medicine and tissue engineering. Her laboratory, in collaboration with J. Upton and C. Vacanti, was the first to combine a degradable scaffold with donor cells to create tissue-engineered cartilage in the shape of a human ear. The 3D Printing Process she co-invented for creation of complex biomaterials scaffolds is used for manufacture of FDA-approved scaffolds for bone regeneration. She is a member of the National Academy of Engineering and the recipient of a MacArthur Foundation Fellowship, and the Popular Science Brilliant 10 Award. She has served as a member of the Advisory Councils for the National Institute for Dental and Craniofacial Research and the National Institute of Arthritis, Musculoskeletal and Skin Diseases at NIH.
Brock Reeve, M.B.A, M.Phil, has been the Executive Director of the Harvard Stem Cell Institute since 2006 where he has overall responsibility for the operations and strategy of the Institute. Brock came to HSCI from the commercial sector with experience in both management consulting and operations for technology-based companies, with a focus on life sciences. Prior to Harvard, Brock was COO and Managing Director of Life Science Insights a consulting and market research firm specializing in information technology in life sciences. As a consultant, Brock focused on the healthcare/life sciences market with IBM, Viant Corp. and SRI Consulting, where his clients included some of the leading pharmaceutical, biotechnology and medical device companies. Brock is on the Board of Directors of Thrive Bioscience and LabMate and is an Advisor to Amasa Technologies and Iviva Medical. Brock is also on the External Advisory Board for the Petit Institute for Bioengineering at Georgia Tech University and on the Board of Trustees for the Pioneer Charter School of Science in Everett, MA. Brock received a BA and MPhil from Yale University and an MBA from Harvard Business School.
Geoffrey Ling, M.D., Ph.D. is the former founding Director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO). Under his leadership DARPA led the development of transformative advances in the field of advanced prosthetics, including the Revolutionizing Prostheses program which successfully created prosthetic upper extremities that were controlled directly by patients' brains. He also served as the Assistant Director for Medical Innovation in President Obama's White House Office of Science Technology Policy (OSTP). A retired Army colonel, Geoffrey is also a practicing neuro-intensive care physician, and a globally-recognized innovator and visionary. Geoff is a Professor of Neurology at both Johns Hopkins University and the Uniformed Services University of the Health Sciences.
George Muschler, M.D. is an internationally-recognized authority on orthopedic regeneration and is a practicing orthopedic surgeon specializing in adult reconstructive surgery and the treatment of fracture non-union. He serves as vice chairman of the Orthopaedic and Rheumatologic Institute in the Cleveland Clinic. Dr. Muschler's laboratory in the Department of Biomedical Engineering at the Cleveland Clinic focuses on stem cell biology, tissue engineering, and regenerative medicine. Dr. Muschler is also the Director of the Clinical Tissue Engineering Center. He served as a co-director of the Armed Forces Institute of Regenerative Medicine (AFIRM). Dr. Muschler is a member of the American Medical Association, American Orthopaedic Association, Association of Bone and Joint Surgeons, Orthopedic Research Society, and International Society for Fracture Repair. He completed fellowships at the Hospital for Special Surgery and at Memorial Sloan Kettering Cancer Center. Dr. Mushcler leads the pre-clinical evaluation of Theradaptive’s therapeutic for long-bone repair.
Michael Yaszemski, M.D., Ph.D. is a globally-recognized authority on spine surgery with appointments as Professor of Orthopedic Surgery and Biomedical Engineering at the Mayo Clinic. He is a member of the U.S. Food & Drug Administration (FDA) Science Board; Co-director, Clinical Trials Oversight Group, Mayo Clinic; on the Editorial board, Journal of Orthopaedic Surgery; and a recipient of the William W. Tipton Jr., M.D., Leadership Award from the American Academy of Orthopaedic Surgeons in 2013. Dr. Yaszemski leads the pre-clinical spinal fusion evaluation of Theradaptive’s therapeutic.
Joseph M. Rosen, M.D. is a Professor of Surgery at Dartmouth-Hitchcock Medical Center in the division of Plastic Surgery and an Adjunct Professor of Engineering at the Thayer School of Engineering at Dartmouth College. His interests span from biomedical engineering to biological warfare. For the past 15 years, Dr. Rosen has acted as a consultant for the Department of Defense. He has chaired various panels to review how we respond to blast injuries on the battlefield and how we can improve all facets of medical response and treatment. Presently, Dr. Rosen is part of a consortium evaluating how regenerative medicine and transplantation can be used to restore wounded warriors to functional independence. He is also the chair of an ad hoc committee for virtual reality and training for ACAPS. Additionally, Dr. Rosen has been involved in relief work internationally for the past 30 years - most recently in Vietnam where he and his team treat children with congenital and traumatic deformities. His work has been widely covered in the media including PBS's NewsHour and Smithsonian magazine.
Claudia Zylberberg, Ph.D. serves as Founder and Chief Executive Officer of Akron Biotech (www.akronbiotech.com) a company that develops, manufactures and markets materials and novel products under cGMP for tissue, cell, and gene therapies. She also co-founded and successfully exited a clinical CRO and a family stem cell bank. Dr. Zylberberg has over 30 years of experience in the international biopharmaceutical industry. She has authored and co-authored many scientific articles and developed several commercial products and patents for use in the field of cellular biology. Due to her vast understanding of the global stem cell market, Dr. Zylberberg has advised and consulted organizations worldwide on the commercialization of cell banking and cell therapies. She participates as an Advisor for the US Pharmacopeia, ISO standards and other international bodies in relation to standard-setting initiatives for biologics and ancillary materials critical for the production of cellular therapies. Among other organizations, she is a member of the National Academy of Science for Regenerative Medicine Forum, BioFlorida Board of Directors, Executive Committee and Treasurer of the Alliance of Regenerative Medicine (ARM) and Treasurer for the NA Region of the International Society of Cell Therapies (ISCT), and Board Member of the National Blood Foundation.